首页> 外文期刊>International journal of clinical pharmacology and therapeutics >The influence of beta-blockade on the hemodynamic effects of levosimendan in elderly (>or= 70 years) patients with acutely decompensated systolic heart failure.
【24h】

The influence of beta-blockade on the hemodynamic effects of levosimendan in elderly (>or= 70 years) patients with acutely decompensated systolic heart failure.

机译:β受体阻滞剂对老年(>或= 70岁)急性失代偿性收缩期心力衰竭患者左西孟旦的血流动力学影响。

获取原文
获取原文并翻译 | 示例
           

摘要

The purpose of this study was to evaluate the influence of chronic beta-blockade on the hemodynamic parameters in elderly (>or= 70 years) patients with acutely decompensated systolic heart failure treated with levosimendan. Eighteen patients with acutely decompensated systolic heart failure (8 on chronic beta-blockade) were included in this study. Inclusion criteria were symptoms and signs of acute heart failure in the presence of: a) left ventricular ejection fraction < 0.35; b) cardiac index < 2.5 l/min/m2, c) pulmonary capillary wedge pressure > 15 mmHg; and d) systolic blood pressure between 90 and 110 mmHg. After completion of baseline hemodynamic measurements, a levosimendan intravenous infusion was started (initial loading dose given as an infusion of 24 microg/kg over 10 minutes, followed by a continuous infusion of 0.1 microg/kg/min for 24 hours). At the end of levosimendan infusion hemodynamic measurements were repeated. Demographic characteristics as well as baseline systolic and diastolic blood pressure were not significantly different between patients not receiving beta-blockers (Group A) and those under beta-blockade (Group B), whereas heart rate was significantly lower in the latter. Treatment with levosimendan was associated with an increase in the cardiac index and a decrease in wedge pressure in both groups (Group A: 43.8% and 33%; p < 0.001 vs. baseline; Group B: 17.72% and 17.5%, p < 0.001 vs. baseline, respectively). Peripheral and pulmonary resistance significantly decreased in both groups (31% vs. 15%, p < 0.001 and 44.5% vs. 25%, p < 0.001, respectively). Thus, the beneficial hemodynamic effects of levosimendan are maintained in elderly patients with acute decompensated systolic heart failure treated with beta-blockers.
机译:这项研究的目的是评估慢性β受体阻滞对左西孟旦治疗的老年(≥70岁)急性失代偿性收缩期心力衰竭患者血液动力学参数的影响。这项研究包括18例急性失代偿性收缩期心力衰竭(8例慢性β受体阻滞)。纳入标准是在以下情况下出现急性心力衰竭的症状和体征:a)左心室射血分数<0.35; b)心脏指数<2.5 l / min / m2,c)肺毛细血管楔压> 15 mmHg; d)收缩压在90至110 mmHg之间。完成基线血液动力学测量后,开始左西孟旦静脉输注(初始负荷剂量为在10分钟内输注24 microg / kg,然后连续输注0.1 microg / kg / min 24小时)。在左西孟旦输注结束时,重复进行血流动力学测量。没有接受β受体阻滞剂治疗的患者(A组)和接受β受体阻滞剂治疗的患者(B组)的人口统计学特征以及基线收缩压和舒张压无明显差异,而后者的心率显着降低。左西孟旦治疗与两组的心脏指数增加和楔形压降低有关(A组:43.8%和33%;相对于基线,p <0.001; B组:17.72%和17.5%,p <0.001相对于基准)。两组的外周阻力和肺阻力均显着降低(分别为31%对15%,p <0.001和44.5%对25%,p <0.001)。因此,左西孟旦的有益血液动力学作用在用β-受体阻滞剂治疗的急性失代偿性收缩性心力衰竭的老年患者中得以维持。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号